Cargando…

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

BACKGROUND: Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this cancer and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giordano, Federica, Vaira, Valentina, Cortinovis, Diego, Bonomo, Sara, Goedmakers, Joyce, Brena, Federica, Cialdella, Annamaria, Ianzano, Leonarda, Forno, Irene, Cerrito, Maria Grazia, Giovannoni, Roberto, Ferri, Gian Luca, Tasciotti, Ennio, Vicent, Silve, Damarco, Francesco, Bosari, Silvano, Lavitrano, Marialuisa, Grassilli, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570906/ https://www.ncbi.nlm.nih.gov/pubmed/31200752 http://dx.doi.org/10.1186/s13046-019-1199-7

Ejemplares similares

p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors
por: Grassilli, Emanuela, et al.
Publicado: (2021)

GSK3A Is Redundant with GSK3B in Modulating Drug Resistance and Chemotherapy-Induced Necroptosis
por: Grassilli, Emanuela, et al.
Publicado: (2014)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation
por: Grassilli, E, et al.
Publicado: (2016)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
por: Sala, Luca, et al.
Publicado: (2019)

Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study
por: Cerrito, Maria Grazia, et al.
Publicado: (2018)

Unexpected frequency of genomic alterations in histologically normal colonic tissue from colon cancer patients
por: Conconi, Donatella, et al.
Publicado: (2016)

Influence of Bruton’s Tyrosine Kinase (BTK) on Epithelial–Mesenchymal Transition (EMT) Processes and Cancer Stem Cell (CSC) Enrichment in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Leichtle, Franziska, et al.
Publicado: (2023)

BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression
por: Betzler, Annika C., et al.
Publicado: (2023)

The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells
por: Romano, Gabriele, et al.
Publicado: (2016)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells
por: Al-Qassab, Yasamin, et al.
Publicado: (2018)

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation
por: Scagliotti, Arianna, et al.
Publicado: (2022)

Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy
por: Pasto, Anna, et al.
Publicado: (2019)

CD133 in Breast Cancer Cells: More than a Stem Cell Marker
por: Brugnoli, Federica, et al.
Publicado: (2019)

Carcinosarcoma of the colon: report of a case with morphological, ultrastructural and molecular analysis
por: Ambrosini-Spaltro, Andrea, et al.
Publicado: (2006)

Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression
por: Forno, Irene, et al.
Publicado: (2015)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

The Glioblastoma Microenvironment: Morphology, Metabolism, and Molecular Signature of Glial Dynamics to Discover Metabolic Rewiring Sequence
por: Virtuoso, Assunta, et al.
Publicado: (2021)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
por: Basile, Debora, et al.
Publicado: (2019)

Short-term Oral Antibiotics Treatment Promotes Inflammatory Activation of Colonic Invariant Natural Killer T and Conventional CD4(+) T Cells
por: Burrello, Claudia, et al.
Publicado: (2018)

Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133(+)/EpCAM(+) phenotype: a promising target for preventing progression of TNBC
por: Brugnoli, Federica, et al.
Publicado: (2017)

The Contrasting Role of p16(Ink4A) Patterns of Expression in Neuroendocrine and Non-Neuroendocrine Lung Tumors: A Comprehensive Analysis with Clinicopathologic and Molecular Correlations
por: Fusco, Nicola, et al.
Publicado: (2015)

Exome Sequencing in an ADSHE Family: VUS Identification and Limits
por: Villa, Chiara, et al.
Publicado: (2022)

Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma
por: Virtuoso, Assunta, et al.
Publicado: (2022)

Long Non-Coding RNAs and Related Molecular Pathways in the Pathogenesis of Epilepsy
por: Villa, Chiara, et al.
Publicado: (2019)

Simultaneous Overexpression of Functional Human HO-1, E5NT and ENTPD1 Protects Murine Fibroblasts against TNF-α-Induced Injury In Vitro
por: Cinti, Alessandro, et al.
Publicado: (2015)

PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem?
por: Narayanan, Shruthi, et al.
Publicado: (2021)

Emerging actionable targets to treat therapy-resistant colorectal cancers
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Identifying Novel Actionable Targets in Colon Cancer
por: Cerrito, Maria Grazia, et al.
Publicado: (2021)

“Ironing out” fasting-induced persister cancer cells to render chemotherapy effective: is this the solution?
por: Grassilli, Emanuela, et al.
Publicado: (2023)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3tfel013uhhh4f0ckvf1ar0ljp